News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medical Prognosis Institute And TD2 Join In Strategic Collaboration To Provide Drug Developers A Unique Multi Biomarker Direct Path To Drug Approval


4/3/2014 10:35:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HOERSHOLM, Denmark and SCOTTSDALE, Ariz., April 3, 2014 (GLOBE NEWSWIRE) -- Medical Prognosis Institute A/S (MPI) - a Danish company and Translational Drug Development LLC (TD2) based in Scottsdale, Arizona, today announced a strategic collaboration offering a proprietary service that defines which initial clinical indication would most likely lead to drug approval. "This technology can dramatically increase the probability of early clinical success" said Dr. Stephen Gately, CEO for TD2.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES